Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy

Journal of Urology

Volumn 193, Issue 4, 2015, Pages 1226-1231

  Morgans, Alicia K ^a   Fan, Kang Hsien ^a,b   Koyama, Tatsuki ^a,b   Albertsen, Peter C ^d   Goodman, Michael ^e   Hamilton, Ann S ^f   Hoffman, Richard M ^g   Stanford, Janet L ^h   Stroup, Antoinette M ⁱ   Resnick, Matthew J ^a   Barocas, Daniel A ^a   Penson, David F ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

Author keywords

antiandrogens; cardiovascular diseases; diabetes mellitus; prostatic neoplasms; risk

Indexed keywords

ANDROGEN; ANTIANDROGEN;

ADULT; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETES MELLITUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPLICATION; DIABETES COMPLICATIONS; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RISK; SURVIVOR; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK; SURVIVORS;

EID: 84926418036     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.11.006     Document Type: Article

References (22)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, Maryland. 2013 Update. Available from http://seer.cancer.gov/csr/1975-2010/. Accessed April 15, 2014.
2. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial Lancet 360 2002 103
3. M.R. Smith Androgen deprivation therapy for prostate cancer: new concepts and concerns Curr Opin Endocrinol Diabetes Obes 14 2007 247
4. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448
5. N.L. Keating, A.J. O'Malley, and S.J. Freedland Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39
6. C.S. Saigal, J.L. Gore, and T.L. Krupski Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493
7. H.K. Tsai, A.V. D'Amico, and N. Sadetsky Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 2007 1516
8. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02 Eur Urol 54 2008 816
9. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92
10. M. Roach, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long term results of RTOG 8610 J Clin Oncol 26 2008 585
11. P.L. Nguyen, Y. Je, and F.A.B. Schutz Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer, a meta-analysis of randomized trials JAMA 306 2001 2359
12. A.M.H. Alibhai, M. Duong-Hua, and R. Sutradhar Impact of Androgen deprivation therapy on cardiovascular disease and diabetes J Clin Oncol 27 2009 3452
13. A.L. Potosky, L.C. Harlan, and J.L. Stanford Prostate cancer practice patterns and quality of life: The Prostate Cancer Outcomes Study J Natl Cancer Inst 91 1999 1719
14. A.L. Potosky, J. Legler, and P.C. Albertsen Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study J Natl Cancer Inst 92 2000 1582
15. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chron Dis 40 1987 373
16. C.N. Klabunde, A.L. Potosky, and J.M. Legler Development of a comorbidity index using physician claims data J Clin Epidemiol 53 2000 1258
17. A.L. Potosky, W.W. Davis, and R.M. Hoffman Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study J Natl Cancer Inst 96 2004 1358
18. C.N. Klabunde, B.B. Reeve, and L.C. Harlan Do patients consistently report comorbid conditions over time? Results from the Prostate Cancer Outcomes Study Med Care 43 2005 391
19. T. Lumley Analysis of complex survey samples J Stat Softw 9 2004 1
20. N.L. Keating, A.J. O'Malley, and S.J. Freedland Does comorbidity influence the risk of myocardial infarction or diabetes during androgen deprivation therapy for prostate cancer? Eur Urol 64 2013 159
21. A.L. Potosky, R. Haque, and A.E. Cassidy-Bushrow Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer J Clin Oncol 32 2014 1324
22. H.H. Chao, T. Mayer, and J. Concato Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy J Investig Med 58 2010 566